Product Information
BUPRENORPHINE 7.5 MCG/HR PATCH is a generic product labeled by Rhodes Pharmaceuticals L.P., priced at $37.6788 per EA under NDC 42858035340. Its NADAC has been published 389 times since Jul 18, 2018.
FDA first approved this application on Jun 30, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
7.5 ug/h
Manufacturer
Rhodes Pharmaceuticals L.P.NDC
42858035340
Classification
Generic
Dosage Form
PATCH
Route
TRANSDERMAL
Effective Date
9/23/2026
Active Ingredients
BUPRENORPHINEApproval Type
Authorized Generic (NDA)
FDA Application
NDA021306FDA Approved
6/30/2010
TE Code
AB
On Market Since
7/3/2017
Pharmacological Classes
Price Statistics
The NADAC for BUPRENORPHINE 7.5 MCG/HR PATCH has been published 389 times since Jul 18, 2018, and over the history we have for it it has declined 43.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $37.6788 per EA |
|---|---|
| All-time high | $72.3075 (Dec 11, 2019) |
| All-time low | $25.3493 (Nov 20, 2024) |
| 52-week high | $37.8502 |
| 52-week low | $30.1197 |
| Median price | $49.9668 |
| Average price | $50.4728 |
| Largest weekly change | +34.4% (Dec 21, 2022) |
| Weeks tracked | 389 |
| Tracking since | Jul 18, 2018 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rhodes Pharmaceuticals L.P. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Buprenorphine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Partial Opioid Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUPRENORPHINE 7.5 MCG/HR PATCH?
The current National Average Drug Acquisition Cost (NADAC) for BUPRENORPHINE 7.5 MCG/HR PATCH, manufactured by Rhodes Pharmaceuticals L.P., is $37.6788 per EA (NDC 42858035340), effective Sep 30, 2026.
How has the price of BUPRENORPHINE 7.5 MCG/HR PATCH changed over time?
Over the history we have for it, the NADAC for BUPRENORPHINE 7.5 MCG/HR PATCH has declined 43.2%. It has been tracked across 389 weekly CMS publications since Jul 18, 2018.
What are the highest and lowest recorded NADAC prices for BUPRENORPHINE 7.5 MCG/HR PATCH?
Since Jul 18, 2018, the NADAC for BUPRENORPHINE 7.5 MCG/HR PATCH has ranged from a low of $25.3493 (Nov 20, 2024) to a high of $72.3075 (Dec 11, 2019), with a median of $49.9668 per EA.
Are there cheaper alternatives to BUPRENORPHINE 7.5 MCG/HR PATCH?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as BUPRENORPHINE 7.5 MCG/HR PATCH in a comparable dosage form, but none are currently priced below it.
Who manufactures BUPRENORPHINE 7.5 MCG/HR PATCH?
BUPRENORPHINE 7.5 MCG/HR PATCH (NDC 42858035340) is labeled by Rhodes Pharmaceuticals L.P., and CMS classifies it as a generic product.